Delight Biopharma Profile
Key Indicators
- Authorised Capital ₹ 9.00 M
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.50 Cr
as on 17-11-2024
- Revenue 73.18%
(FY 2023)
- Profit 101.75%
(FY 2023)
- Ebitda 70.78%
(FY 2023)
- Net Worth 49.81%
(FY 2023)
- Total Assets 20.29%
(FY 2023)
About Delight Biopharma
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 9.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.50 Cr.
Raghavendar Bussa and Hemalatha Koyyana serve as directors at the Company.
- CIN/LLPIN
U24303TG2017PTC119054
- Company No.
119054
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Aug 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Delight Biopharma Private Limited offer?
Delight Biopharma Private Limited offers a wide range of products and services, including Brain & Nervous System Drugs, Antiepileptic Drugs, Common Disease Medicines, Skin Lightening Drugs, Anti Infective Drugs & Medicines, Antibiotic Injection, Cardiovascular Drugs & Medication, Anticoagulant and Antiplatelet Drugs, Antibacterial Drugs, Digestive System Drugs & Medicines.
Who are the key members and board of directors at Delight Biopharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raghavendar Bussa  | Additional Director | 04-Mar-2024 | Current |
| Hemalatha Koyyana | Director | 23-Aug-2017 | Current |
Financial Performance of Delight Biopharma.
Delight Biopharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 73.18% increase. The company also saw a substantial improvement in profitability, with a 101.75% increase in profit. The company's net worth Soared by an impressive increase of 49.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Delight Biopharma?
In 2023, Delight Biopharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 31 Jul 2024 | ₹1.50 Cr | Open |
How Many Employees Work at Delight Biopharma?
Delight Biopharma has a workforce of 32 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Delight Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Delight Biopharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
